Research context. CJC-1295 without DAC is a modified GHRH analogue used to study shorter-duration GHRH-receptor signalling. Findings from experimental models do not establish clinical safety or efficacy.
CJC-1295 NO DAC — Technical Research Profile
| Research classification |
Non-DAC modified GHRH(1-29) analogue |
| Available size(s) |
2MG, 5MG |
| Primary research system |
Growth-hormone-releasing hormone receptor (GHRHR); Gs–cAMP–PKA signalling |
Molecular and structural context
CJC-1295 without DAC is commonly identified with modified GRF(1-29), a 29-residue GHRH analogue containing substitutions that improve resistance to enzymatic cleavage. It lacks the albumin-reactive DAC group.
Mechanistic research framework
The analogue activates GHRHR, a class B GPCR, producing cAMP and PKA-dependent signalling. Removal of DAC principally changes disposition and exposure kinetics relative to the albumin-binding form.
Laboratory applications include receptor activation, release kinetics, dose-response behavior, and comparison with DAC-modified analogues.
Experimental applications and endpoint selection
Studies may compare cAMP potency, receptor desensitization, proteolytic stability, pulse duration, and endocrine-response kinetics with native GHRH and CJC-1295 DAC. Sampling frequency should be sufficient to resolve shorter-duration responses.
This material is intended for analytical, biochemical, receptor-pharmacology, cellular, or other controlled preclinical workflows as appropriate to the target system. Study design should define the biological matrix, exposure duration, concentration range, replicate structure, acceptance criteria, and statistical plan before data collection.
Principal areas of scientific inquiry
- GHRH-receptor activation
- Short-duration signalling kinetics
- DAC versus non-DAC analogue comparisons
Technical keywords
- Modified GRF(1-29)
- GHRHR agonism
- Short-duration signalling
- DAC comparison
Analytical characterization considerations
Sequence substitutions, truncation products, oxidation, and terminal state should be monitored. LC-MS, peptide mapping or high-resolution intact mass, RP-HPLC, and GHRHR bioassays can support characterization.
Where scientifically appropriate, laboratories may use orthogonal methods such as reversed-phase HPLC for chromatographic purity, LC-MS for molecular identity, size-sensitive methods for aggregation, and a target-relevant functional assay for biological activity. Method suitability, reference standards, system suitability, and acceptance limits must be independently established; these examples are not batch-specific analytical claims.
Study design and interpretation
Use vehicle, positive, negative, and concentration-matched controls appropriate to the assay. Receptor expression, biological matrix, incubation time, adsorption, proteolysis, passage number, and species background can all change apparent potency or pathway output. Observations from in vitro or animal models should not be extrapolated to human use.
Handling and documentation
Use calibrated equipment and documented receipt, storage, preparation, aliquoting, freeze-thaw, and disposal procedures. Solvent compatibility, working concentration, stability window, container adsorption, and assay recovery must be established by the purchasing laboratory using the applicable batch documentation and institutional standard operating procedures.
Important compliance and safety remarks
- No therapeutic, diagnostic, cosmetic, or veterinary claims are made.
- Work must be performed by qualified personnel under applicable institutional and regulatory requirements.
- Use appropriate personal protective equipment and controlled laboratory procedures.
For research use only. Not for human or animal consumption.
Research-use notice. This material is supplied solely for legitimate research and analytical purposes. Researchers are responsible for material suitability, laboratory safety, and compliance with all applicable requirements.
Reviews
There are no reviews yet.